Skip to main content
. 2022 Jul 26;34(2):133–147. doi: 10.4103/joco.joco_308_21

Figure 6.

Figure 6

Estimated weighted mean difference of baseline to 12-month (pictured top), and baseline to 24-month best-corrected visual acuity (pictured bottom) with aflibercept therapy as measured using Early Treatment Diabetic Retinopathy Study (ETDRS) letters. Dashed line represents weighted mean difference. 12-month weighted mean difference: 9.31 ETDRS letters, P < 0.001. 24-month weighted mean difference: 6.76 ETDRS letters, P = 0.056. Values reported as crude mean difference, without adjustment for covariates. CI: Confidence interval